Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression
Neurobiology of Disease · 2023
DOI: 10.1016/j.nbd.2023.106108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2023. Verfasst von Walid Khrouf und 30 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP.Sorbonne Université, DMU Biogem-Metabolic Biochemistry department, Neurometabolic and Neurodegenerative Unit - Hôpital Pitié-Salpêtrière, 75013…. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Pick Disease of the Brain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
GRN mutations are among the main genetic causes of frontotemporal dementia (FTD). Considering the progranulin involvement in lysosomal homeostasis, we aimed to evaluate if plasma lysosphingolipids (lysoSPL) are increased in GRN mutation carriers, and whether they might represent relevant fluid-based biomarkers in GRN-related diseases. We analyzed four lysoSPL levels in plasmas of 131 GRN carriers and 142 non-carriers, including healthy controls and patients with frontotemporal dementias (FTD) carrying a C9orf72 expansion or without any mutation. GRN carriers consisted of 102 heterozygous FTD patients (FTD-GRN), three homozygous patients with neuronal ceroid lipofuscinosis-11 (CLN-11) and 26 presymptomatic carriers (PS-GRN), the latter with longitudinal assessments. Glucosylsphingosin d18:1 (LGL1), lysosphingomyelins d18:1 and isoform 509 (LSM18:1, LSM509) and lysoglobotriaosylceramide (LGB3) were measured by electrospray ionization-tandem mass spectrometry coupled to ultraperformance liquid chromatography. Levels of LGL1, LSM18:1 and LSM509 were increased in GRN carriers compared to non-carriers (p < 0.0001). No lysoSPL increases were detected in FTD patients without GRN mutations. LGL1 and LSM18:1 progressively increased with age at sampling, and LGL1 with disease duration, in FTD-GRN. Among PS-GRN carriers, LSM18:1 and LGL1 significantly increased over 3.4-year follow-up. LGL1 levels were associated with increasing neurofilaments in presymptomatic carriers. This study evidences an age-dependent increase of β-glucocerebrosidase and acid sphingomyelinase substrates in GRN patients, with progressive changes as early as the presymptomatic phase. Among FTD patients, plasma lysoSPL appear to be uniquely elevated in GRN carriers, and thus might serve as suitable non-invasive disease-tracking biomarkers of progression, specific to the pathophysiological process. Finally, this study might add lysoSPL to the portfolio of fluid-based biomarkers, and pave the way to disease-modifying approaches based on lysosomal function rescue in GRN diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP.Sorbonne Université, DMU Biogem-Metabolic Biochemistry department, Neurometabolic and Neurodegenerative Unit - Hôpital Pitié-Salpêtrière, 75013 Paris, France.
- Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team, Inria Research Center of Paris, Paris, France; A…
- Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France; AP-HP - Reference Centre for Rare or Early onset Dementias, IM2A, Dep…
- AP-HP.Sorbonne Université, Department of Genetics, UF of Molecular and Cellular Neurogenetics, - Hôpital Pitié-Salpêtrière, 75013 Paris, France.
- Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France.
- Univ Lille, Inserm 1172 LilNCOG, CHU Lille, CNR-MAJ, DistAlz, LiCEND 59000 Lille, France.
Zitieren
APA
Khrouf, W., Saracino, D., Rucheton, B., Houot, M., Clot, F., Rinaldi, D., Vitor, J., Huynh, M., Heng, E., Schlemmer, D., Pasquier, F., Deramecourt, V., Auriacombe, S., Azuar, C., Levy, R., Bombois, S., Boutoleau-Brétonnière, C., Pariente, J., Didic, M., …, & Lamari, F. (2023). Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2023.106108
Vancouver
Khrouf W, Saracino D, Rucheton B, Houot M, Clot F, Rinaldi D, et al. Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression. Neurobiology of Disease. 2023. doi:10.1016/j.nbd.2023.106108
BibTeX
@article{Khrouf2023,
author = {Khrouf, Walid and Saracino, Dario and Rucheton, Benoit and Houot, Marion and Clot, Fabienne and Rinaldi, Daisy and Vitor, Joana and Huynh, Marie and Heng, Evelyne and Schlemmer, Dimitri and Pasquier, Florence and Deramecourt, Vincent and Auriacombe, Sophie and Azuar, Carole and Levy, Richard and Bombois, Stéphanie and Boutoleau-Brétonnière, Claire and Pariente, Jérémie and Didic, Mira and Wallon, David and Fluchère, Frédérique and Auvin, Stéphane and Younes, Imen Ben and French clinical and genetic research network on FTD/FTD-ALS, French clinical and genetic research network on FTD/FTD-ALS and Predict-PGRN study group, Predict-PGRN study group and Nadjar, Yann and Brice, Alexis and Dubois, Bruno and Bonnefont-Rousselot, Dominique and Le Ber, Isabelle and Lamari, Foudil},
title = {Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression},
journal = {Neurobiology of Disease},
year = {2023},
doi = {10.1016/j.nbd.2023.106108}
}
EUVIMED